Renal dosing of allopurinol results in suboptimal gout care
Ann Rheum Dis
.
2017 Jan;76(1):e1.
doi: 10.1136/annrheumdis-2016-210352.
Epub 2016 Aug 31.
Authors
Tuhina Neogi
1
,
Nicola Dalbeth
2
,
Lisa Stamp
3
,
Geraldo Castelar
4
,
John Fitzgerald
5
,
Angelo Gaffo
6
7
,
Ted R Mikuls
8
,
Jasvinder Singh
7
,
Janitzia Vázquez-Mellado
9
,
N Lawrence Edwards
10
Affiliations
1
Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, Massachusetts, USA.
2
Department of Immunology, University of Auckland, Auckland, New Zealand.
3
Department of Medicine, Otago University, Christchurch, Canterbury, New Zealand.
4
Department of Rheumatology, Pedro Ernesto University Hospital, Rio de Janeiro, Brazil.
5
Medicine/Rheumatology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
6
Department of Medicine, Birmingham VA Medical Center, Birmingham, Alabama, USA.
7
Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
8
Department of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
9
Servicio de Reumatologia, Hospital General de Mexico, Mexico City, Mexico.
10
Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA.
PMID:
27582422
DOI:
10.1136/annrheumdis-2016-210352
No abstract available
Keywords:
Arthritis; Gout; Treatment.
Publication types
Letter
Comment
MeSH terms
Allopurinol*
Gout Suppressants
Gout*
Humans
Kidney
Uric Acid
Substances
Gout Suppressants
Uric Acid
Allopurinol